All News
Pulse Steroids with Tocilizumab in Giant Cell Arteritis
A pilot study assessed pulse methoprednisolone with weekly subcutaneous tocilizumab (TCZ) in patients with large vessel-GCA (LV-GCA) and showed that a sizeable minority will relapse after the TCZ is discontinued.
Sequential Belimumab and Rituximab in SLE
Could disease control in active systemic lupus erythematosus (SLE) patients be improved by the sequential use of subcutaneous belimumab (BEL) and intravenous rituximab (RTX)? A double blind trial has shown that sequential BEL and RTX was not superior to BEL alone in SLE.
Read Article
Severe Alopecia Areata or Universalis - if you stop the JAK inhibitor, Hair loss occurs quickly, but can be recaptured. Severe Alopecia Areata. Substudy of the baricitinib BRAVE-AA1 RCT, 80% of those who D/C vs 8% of those continuing, lost BARI benefits https://t.co/YcfmegdvK6 https://t.co/GIwVy4ac6U
Dr. John Cush RheumNow ( View Tweet)
Global Biologics Market size is valued at USD 408.5 billion in 2023 and is projected to grow ~8.25% annually. https://t.co/2RTHIgJOP5 https://t.co/gfndut5wc0
Dr. John Cush RheumNow ( View Tweet)
Higher Cancer Rates (8.16.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on https://t.co/V10S4oVFsv, noting his concerns about diet, cancer, ILD, death and dosing challenges.
https://t.co/thNOPkYWRM https://t.co/ZFwvE80e7Q
Dr. John Cush RheumNow ( View Tweet)
From 25K prediabetics, 1,521 had serial serum Uric acid measures. Predictors of increaed SU levels included Older age, male sex, greater BMI, and higher HbA1c. Those w/ a BMI ≥30 kg/m2 exhibited higher SU levels https://t.co/ztp8M781Dw https://t.co/PNaZxMIOlG
Dr. John Cush RheumNow ( View Tweet)
100 top-cited studies in #SLE. 60% from USA; half focused on underlying mechanisms
#1 1982 1982 Revised Criteria for.. Classification ..SLE
#2 Updated ACR Criteria...
#3 Derivation of SLEDAI https://t.co/g3fcUqtsct https://t.co/HlGfGC4aci
Dr. John Cush RheumNow ( View Tweet)
🔥 One of the most important articles of the year showing medical evidence for disease-modifying (organ damage prevention) therapies in #SLE #lupus:
CLICK 👉 https://t.co/Qmia9Gc8mu
Kudos to the authors for such an important piece of work. Open up the table in the article and… https://t.co/z9osFAavud https://t.co/lWjkwMEHrq
Links:
Donald Thomas, MD lupuscyclopedia ( View Tweet)
IgG4-related disease
Nearly any organ can be affected
▶️Salivary glands
▶️Lacrimal glands
▶️Orbit
▶️Pancreatobiliary system
▶️Lung
▶️Kidney
▶️Retroperitoneum
👉🏽https://t.co/758F5iuYwT
via @RheumJnl https://t.co/ipONrygHmc
Links:
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
New! 📣Best Practice Guidelines for the management of Haemophagocytic Lymphohistiocytosis (HLH) aka Macrophage Activation Syndrome (MAS) from @NHSGIRFT @RheumatologyUK Remember the 3Fs Fever, Falling Counts, Ferritin and follow the HLH pathway to guide management… https://t.co/8oDyUbsm9W https://t.co/S0MDi3TkNk
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Metanalysis of 50 RCTs (3,231 pts w/ lupus nephritis (LN) related starting pred dose to rates of complete response (CR), serious infections, & death. PO pred 25 mg/D assoc w/ 20%, 3.2% & 0.2%, respectively. Pred 60 mg/day incr rates to 35%, 12% & 2.7% https://t.co/6FH9BWsmaz https://t.co/0cQPAIuvRw
Dr. John Cush RheumNow ( View Tweet)
ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis
Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to SEC 300 mg, but failed to show improvement by week 52.
https://t.co/EJvoBlW9or https://t.co/tYb1fIA3pw
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 12 studies shows that being edentulous (or having < 20 teeth) was associated w/ higher risk (HR 1.66; 1.32–2.09) critical confounders also confirmed that tooth loss as a risk factor for Cardiovascular mortality (HR=1.52, 95% CI: 1.28–1.80) https://t.co/PStGlxmCC3 https://t.co/ZDzaytj9dY
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 16 RCTs shows febuxostat reduces the risk of kidney events (RR = 0.56, 95% CI 0.37-0.84, p = 0.006) and a slower decline in eGFR (vs controls) https://t.co/9YAxTrHFVQ https://t.co/ZyRE7R6P4a
Dr. John Cush RheumNow ( View Tweet)
Anti-CD40 Therapy in Sjögren's Disease
Iscalimab, a CD40 monoclonal antibody, showed + results in treating Sjögren's disease, an autoimmune condition lacking effective therapy. The TWINSS study demonstrated iscalimab's safety/efficacy in a phase 2 trial.
https://t.co/aanI9K83XP https://t.co/qJhgHDFCVY
Dr. John Cush RheumNow ( View Tweet)
Pregnancy, menopause, contraceptives, hormone replacement, aromatase inhibitors may affect lupus outcomes. Review says hormone therapies are contraindicated w/ antiphospholipid syndr, APL Ab positivity, and uncontrolled SLE or flares https://t.co/bZQr8b871n https://t.co/OmXY04GR4p
Dr. John Cush RheumNow ( View Tweet)
Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease
A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD.
https://t.co/J9FCdkId8H https://t.co/uJylDP3IIp
Dr. John Cush RheumNow ( View Tweet)
Romosozumab vs. Teriparatide in Postmenopausal Osteoporosis
The effectiveness/safety of ROMO and TPTD were compared in a clinical setting, and ROMO showed greater increases in BMD than TPTD after 12 months of therapy, along with a higher completion rate.
https://t.co/iKKLruiiay https://t.co/vPKa8pom7e
Dr. John Cush RheumNow ( View Tweet)
Anti-Inflammatory Diet yields a lower risk of Dementia. UK Biobank study shows patients w/ type 2 diabetes, heart disease, or stroke who were on an anti-inflammatory diet had a 31% lower risk for dementia vs. a pro-inflammatory diet https://t.co/OjHq3BBOfd https://t.co/tG9vO59IEc
Dr. John Cush RheumNow ( View Tweet)
Hispanic Patients With Dermatomyositis
JAMA Dermatology has published a review of dermatomyositis (DM), focusing on similar and different manifestations of DM.
https://t.co/HydzbzTJR4 https://t.co/KJs681ySO7
Dr. John Cush RheumNow ( View Tweet)